Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 25/04/2024
In
Objective
To achieve long-term capital growth by investing in biotechnology and other life sciences companies.
AIC sector
Management group
Schroder Investment Management
Company website
Launch date
06/05/1994
August
Domicile
United Kingdom
Fund manager
Ailsa Craig, Marek Poszepczynski
Dividend frequency
Semi-Annually
Wind-up provisions
The Association Articles of the company provide for Directors to put forward a proposal for the continuation of the company at the AGM at two-yearly intervals. The upcoming continuation vote is scheduled for the December 2025 AGM.
Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
---|---|---|---|---|---|---|---|---|
228.69 | 282.41 | 606.00 | 673.48 | -10.02 | 10 | 4.65 | Jul, Dec | 1.4 (31/08/2023) |
Scroll
Dividends
Dividends declared in last 12 months
Ex-Dividend date | Payment date | Dividend amount | Special dividend | Financial year |
---|---|---|---|---|
21/12/2023 | 26/01/2024 | 13.900 | No | 2024 |
27/07/2023 | 25/08/2023 | 14.200 | No | 2023 |
Scroll
Performance (%)
Return type | 1 year | 3 years | 5 years | 10 years | |
---|---|---|---|---|---|
International Biotechnology | Share price total return | -5.1 | -7.1 | 19.0 | 207.3 |
Biotechnology & Healthcare AIC sector | Share price total return | -3.0 | -21.1 | 2.5 | 129.2 |
Scroll
Share structure
Number of shares
37,737,787
3,646,030
Traded volumes (number of shares)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 42,457 | 1,187,798 | 12,934,869 | 82,788,582 |
Average | N/A | 56,555 | 51,231 | 65,599 |
Scroll
Traded values (m)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 0.26 | 7.54 | 82.44 | 569.18 |
Average | N/A | 0.36 | 0.33 | 0.45 |
Scroll
Trading details
Top holdings
Data as at : 31/03/2024
Investment | % of total assets |
---|---|
Amgen Inc | 5.6 |
Cytokinetics Inc | 5.1 |
Sv Fund Vi Investment | 4.8 |
Gilead Sciences Inc | 4.4 |
Vera Therapeutics Inc Class A | 4.3 |
Biomarin Pharmaceutical Inc | 4.3 |
Incyte Corp | 3.7 |
Supernus Pharmaceuticals Inc | 3.5 |
Alnylam Pharmaceuticals Inc | 3.4 |
Scb Sholo211123b 20-Mar-2024 6.46% 22-Apr-2024 | -10.0 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.